The Center for Urologic Oncology at the Glickman Urological & Kidney Institute is the largest center within the Department of Urology.
The membership of the Center boasts 10 fellowship-trained, internationally-recognized leaders in bladder, kidney, prostate, and testis cancer who are supported by an integrated team of experienced mid-level practitioners (including nurse practitioners and physicians assistants).
The surgeons within the Center perform robotic and open procedures to treat these cancers, often in a multi-disciplinary team approach with the integration of expertise by medical oncology and/or radiation oncology.
The Center has a rich history of technical innovations which have transformed the management of these cancers including open partial nephrectomy, laparoscopic/robotic partial nephrectomy, radical nephrectomy and venous thrombectomy for advanced kidney cancer, open/robotic radical prostatectomy and robotic radical cystectomy.
The Center has also been at the forefront of pioneering less-invasive treatment alternatives (where appropriate) for urologic cancers such as active surveillance, cryotherapy, and focal therapy for localized prostate cancer and percutaneous ablative procedures for small renal masses.
Annually, surgeons within the Center perform approximately 500 partial/radical nephrectomy procedures for kidney cancer, 450 prostatectomy procedures for prostate cancer, 140 cystectomy procedures for bladder cancer, and 40 retroperitoneal lymph node dissections for testis cancer.
The Center has unique expertise in managing rare urologic cancers (such as cancers of the penis, urethra, adrenal gland, and genitourinary sarcomas) and salvage procedures for recurrent cancers of the bladder and prostate that have failed initial therapy with radiation or other treatments.
The clinical activities of the Center are supported by world-class clinical experts in pathology, radiology, and anesthesia.
The Center also supports research programs in patient-centered outcomes research, prostate cancer/androgen receptor biology, and kidney cancer.